KYMR · Kymera Therapeutics, Inc.

The thesis

Kymera Therapeutics trades on one event: whether KT-621, its once-daily oral STAT6 degrader, shows efficacy close to the injectable Dupixent in the Phase 2b BROADEN2 trial in atopic dermatitis (eczema). Topline results are guided for year-end 2026, and that readout settles the case. The quarterly report on 29 October 2026 comes first and can confirm or move that timing.

The last completed close on 26 October 2026 was $114.84. That is 9.8% below the $127.31 52-week high and 9.1% higher over three months, with a 14-day relative strength index (RSI) of 63.7. The close on 13 October 2026 was $106.68, so the shares have recovered the weakness that was visible in the prior note.

Kymera announced on 22 October 2026 that it will report third-quarter 2026 results on 29 October 2026, with a call at 8:30 a.m. ET. No topline data and no SEC filing have appeared since the 5 August 2026 second-quarter results.

The narrative is maturing: the oral-STAT6 story has been public since the 25 June 2026 enrollment announcement, and analysts have raised targets or ratings or initiated coverage repeatedly since 27 August 2026 (Citigroup, Raymond James, Stifel, BofA Securities, Wolfe Research). A weekly close above $127.31 before topline would show new buying and overturn the view that most of the good news is already known.

Bullish and bearish views on Kymera Therapeutics, Inc.

The bull case on Kymera Therapeutics, Inc. (KYMR), in brief: The readout moved forward and is funded. The bear case: The bar is a biologic.

Bull case

• The readout moved forward and is funded. Kymera said on 25 June 2026 that BROADEN2 enrollment finished nearly six months early, pulling topline to year-end 2026. The 5 August 2026 release reported $1.5 billion in cash, cash equivalents and investments at 30 June 2026, with runway into 2029.
• Partners are paying for the platform. Second-quarter 2026 collaboration revenue was $65.0 million, including a $45 million payment when Gilead exercised its KT-200 option and a $20 million Sanofi milestone for dosing KT-485 (5 August 2026 release). Both deals sit outside KT-621.
• Sell-side coverage is broad. Raymond James initiated at Outperform with a $140 target on 9 October 2026, and Citigroup raised its target to $150 on 5 October 2026. Stifel ($152, 22 September 2026), BofA Securities ($144, 14 September 2026), Guggenheim ($170, 31 August 2026) and Wells Fargo ($151, 27 August 2026) acted earlier.
• JPMorgan framed the upside. On 28 September 2026 analyst Brian Cheng placed the stock on Positive Catalyst Watch with an Overweight rating and a $140 target, estimating 65% to 85% upside if KT-621 shows Dupixent-comparable efficacy with clean safety (GuruFocus).
• A second readout lands in the same quarter. Kymera guides Phase 1 healthy-volunteer data for KT-579, its IRF5 degrader, in Q4 2026 (5 August 2026 release).

Bear case

• The bar is a biologic. BROADEN2 is placebo-controlled, with the percentage change in the Eczema Area and Severity Index (EASI) score at week 16 as its primary endpoint. JPMorgan's upside case assumes Dupixent-comparable efficacy, so a win over placebo that trails that benchmark could still disappoint.
• The shares have moved ahead of the data. The close rose from $106.68 on 13 October 2026 to $114.84 on 26 October 2026, and the RSI of 63.7 sits well above the 35.3 reading on the earlier date. The consensus target of $133.21 (MarketBeat, 1 October 2026) is the sell-side's own estimate of what a positive result is worth.
• No product revenue. All revenue is collaboration and milestone income. Second-quarter 2026 R&D expense was $119.5 million and the net loss $61.2 million (5 August 2026 release), so the valuation rests on pipeline outcomes.
• The timing is a window. Kymera guides to "by year-end 2026" without a date. If the readout slips into 2027, the near-term catalyst the current price reflects disappears.

Price setup

The 26 October 2026 close of $114.84 sits 9.8% under the 52-week high of $127.31. The shares have risen from the 13 October 2026 close of $106.68 and gained 9.1% over three months (adjusted daily closes).

Crowding evidence is moderate. The quarterly report is three days away, analyst coverage is heavy (26 analysts in MarketBeat's 1 October 2026 count), and the RSI of 63.7 shows buying has picked up. No insider sales or share issuance have been reported in SEC filings since the prior note.

Two levels frame the next weeks. A daily close below $106, under the 13 October 2026 close, would erase the recent recovery. A weekly close above $127.31 would be a new 52-week high.

Catalysts, next 30 days

• ~2026-12 (est.): KT-579 Phase 1 data. Guided for the fourth quarter; it falls outside the 30-day window but matters for the platform case.
• 31 December 2026: guided BROADEN2 topline deadline. Also outside the window; a missed date would break the timing case.

Elapsed catalysts

• 29 October 2026: third-quarter 2026 results. Kymera reports with a call at 8:30 a.m. ET. The release updates cash and runway and is the likeliest place for any change to the BROADEN2 timing. (passed 8d ago)

What would change the view

The case breaks if BROADEN2 misses its week-16 EASI primary endpoint, if topline guidance moves into 2027 at the 29 October 2026 report, or if 31 December 2026 passes with no results. A result that beats placebo but trails Dupixent benchmarks would weaken the upside cases that analysts cite, including JPMorgan's.

On price, a daily close below $106, under the 13 October 2026 close of $106.68, would show the recent recovery has failed. A weekly close above $127.31 before topline would show the market pricing a positive result with more confidence than the current evidence supports.

What it trades with

KYMR trades on its own clinical event more than on sector moves. Sanofi news matters in both directions: Sanofi is a Kymera partner (KT-485 milestone, 5 August 2026) and funds Recludix's rival oral STAT6 program. Read-across from other oral or injectable eczema programs can also move the shares, as can broad swings in small and mid-cap biotech.